New drugs help Pfizer beat expectations
Sales of breast cancer treatment more than tripled in Q2
Pharmaceutical giant Pfizer has reported second-quarter earnings that beat analysts’ estimates, thanks to strong sales of its newest drugs for cancer and rheumatoid arthritis.
Sales of Ibrance, Pfizer’s new breast cancer treatment, more than tripled to $514m. The drug generated $723m last year, its first on the market, and analysts surveyed by Bloomberg predict annual sales will reach $4.81 billion by 2018.
Second-quarter sales of Pfizer’s rheumatoid arthritis drug Xeljanz were $217m, ahead of...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Analysis: At what point could Covid-19 be reasonably compared to a cold or flu?
Covid-19’s levels of fatality far exceed flu, but Omicron’s reduced severity combined with boosters and the arrival of antiviral pills may change that
Ten steps to save yourself at least €5,000 in 2022
From switching credit card provider to making your own sandwich in the morning, there are many ways you can keep more cash in your pocket for the things you want to do
Dan O’Brien: Our national inferiority complex fuels the move towards angry populism
Ireland is a reasonably well-functioning country by European standards, but you wouldn’t think it to listen to the rising number of ‘failed staters’
Aidan Regan: ‘One size fits all’ doesn’t work for Europe’s many varieties of capitalism
If we want to see a truly pan-European growth model, we should be hoping that the fiscal conservatives of the European Council are outflanked by a new progressive Franco-Italian-Iberian alliance